Key facts
- This page summarizes Todd Shegog's Form 4 filing for Forma Therapeutics Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2022, 16:11.
Todd Shegog - 28 Feb 2022 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.
- Reporting relationship
- SVP, Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 28 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2022, 16:11:33 UTC
- Prior SEC filing
- 25 Feb 2022
- Next SEC filing
- 09 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeannette Potts, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Todd Shegog filed Form 4 for Forma Therapeutics Holdings, Inc. on 02 Mar 2022.
Change
- Previous filing in this sequence was filed on 25 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FMTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +33,330
- Change %
- +146%
- Price
- $0.000000
- Shares after
- 56,143
- Date
- 28 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FMTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 28 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $9.86
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
Footnote F2
25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.